Quantinno Capital Management LP Purchases 21,794 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Quantinno Capital Management LP boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 180.2% during the 1st quarter, HoldingsChannel.com reports. The firm owned 33,885 shares of the biopharmaceutical company’s stock after purchasing an additional 21,794 shares during the period. Quantinno Capital Management LP’s holdings in Catalyst Pharmaceuticals were worth $839,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Advisory Services Network LLC purchased a new position in Catalyst Pharmaceuticals in the third quarter worth about $39,000. Quarry LP purchased a new stake in shares of Catalyst Pharmaceuticals during the third quarter valued at approximately $40,000. Clearstead Advisors LLC grew its holdings in shares of Catalyst Pharmaceuticals by 192.9% during the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 1,167 shares during the last quarter. Smartleaf Asset Management LLC increased its position in shares of Catalyst Pharmaceuticals by 55.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 630 shares in the last quarter. Finally, Larson Financial Group LLC increased its position in shares of Catalyst Pharmaceuticals by 552.7% during the fourth quarter. Larson Financial Group LLC now owns 1,847 shares of the biopharmaceutical company’s stock valued at $43,000 after acquiring an additional 1,564 shares in the last quarter. 79.22% of the stock is currently owned by institutional investors.

Catalyst Pharmaceuticals Price Performance

Shares of CPRX stock opened at $31.49 on Tuesday. The company has a 50 day moving average price of $31.46 and a 200-day moving average price of $28.26. Catalyst Pharmaceuticals, Inc. has a 52 week low of $19.05 and a 52 week high of $32.56. The firm has a market capitalization of $3.86 billion, a PE ratio of 18.10, a P/E/G ratio of 0.96 and a beta of 0.74.

Analysts Set New Price Targets

Several equities analysts recently issued reports on CPRX shares. Wall Street Zen cut Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. HC Wainwright lowered Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $35.00 to $31.50 in a report on Thursday, May 28th. Robert W. Baird cut Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 7th. Weiss Ratings raised Catalyst Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a report on Wednesday, June 3rd. Finally, Stephens set a $32.00 price target on Catalyst Pharmaceuticals in a report on Thursday, May 7th. Two research analysts have rated the stock with a Strong Buy rating, one has given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $32.00.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).